Interactions between anticancer drugs and other clinically used pharmaceuticals. A review.
Drug interactions are increasingly common, since clinical practice is getting more complex with the flood of new drugs. Simultaneously, the increased life expectancy of the population increases the number of individuals likely to receive multiple prescriptions. Cytotoxic drugs generally have a narrow therapeutic index, and are delivered at doses close to toxic levels. Consequently, a slight increase in biological activity caused by an interaction with other concomitantly administered drugs could be deleterious to the patient. Interactions between drugs can sometimes also be used in a positive way, i.e. to increase the therapeutic ratio and overcome drug resistance. Interactions between different cancer treatment modalities have attracted considerable interest. However, much less interest has been devoted to interactions between anticancer drugs and other pharmaceuticals. The purpose of this review is to summarize data about the interactions between anticancer drugs and other clinically used drugs with regard to effects on tumor and toxicity.
Henriksson
R
R
Department of Oncology and Clinical Chemistry, Umeå University Hospital, Sweden.
Grankvist
K
K
D000700:Analgesics / Q000494:pharmacology; D000777:Anesthetics / Q000494:pharmacology; D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology; D000932:Antiemetics / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001993:Bronchodilator Agents / Q000494:pharmacology; D015220:Calcium Channels / Q000187:drug effects; D002317:Cardiovascular Agents / Q000494:pharmacology; D004347:Drug Interactions; D006801:Humans
D000700:Analgesics; D000777:Anesthetics; D000890:Anti-Infective Agents; D000932:Antiemetics; D000970:Antineoplastic Agents; D001993:Bronchodilator Agents; D015220:Calcium Channels; D002317:Cardiovascular Agents